Syon Capital LLC Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Syon Capital LLC acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,306 shares of the company's stock, valued at approximately $320,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. Hood River Capital Management LLC lifted its stake in shares of Revolution Medicines by 25.9% during the fourth quarter. Hood River Capital Management LLC now owns 1,678,434 shares of the company's stock valued at $73,415,000 after buying an additional 345,622 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Revolution Medicines by 10.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,865,962 shares of the company's stock valued at $256,578,000 after buying an additional 552,657 shares during the period. Rock Springs Capital Management LP increased its position in Revolution Medicines by 20.1% during the fourth quarter. Rock Springs Capital Management LP now owns 1,213,257 shares of the company's stock worth $53,068,000 after purchasing an additional 203,312 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Revolution Medicines by 672.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,479 shares of the company's stock worth $808,000 after purchasing an additional 16,087 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in Revolution Medicines by 16.1% during the fourth quarter. MetLife Investment Management LLC now owns 100,329 shares of the company's stock worth $4,388,000 after purchasing an additional 13,918 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Insider Buying and Selling

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares in the company, valued at $4,489,834.24. This represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark A. Goldsmith sold 11,738 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the sale, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. The trade was a 2.59 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently commented on RVMD. Stifel Nicolaus dropped their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $59.00 price target on shares of Revolution Medicines in a research report on Tuesday, April 8th. Wedbush reaffirmed an "outperform" rating and set a $67.00 price target on shares of Revolution Medicines in a research report on Monday. UBS Group upped their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright upped their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $66.67.

Revolution Medicines Stock Up 0.3 %

Shares of Revolution Medicines stock traded up $0.13 during trading hours on Thursday, hitting $40.51. 473,324 shares of the company's stock traded hands, compared to its average volume of 1,444,519. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The company has a market cap of $7.53 billion, a PE ratio of -11.27 and a beta of 1.37. The stock has a 50 day simple moving average of $37.36 and a 200-day simple moving average of $43.90.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, equities research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.